SBI Misses the Mark? 🏦 | Biocon’s 7-Product Launch & The GLP-1 Boom!... 08-May-26
A mixed bag on Dalal Street! SBI’s standalone profit hit ₹19,684 crore, but the stock faced pressure after missing analyst estimates. Join us as we break down the banking giant's Q4 scorecard and Biocon’s ambitious roadmap for North America. We discuss the potential of Biocon’s GLP-1 portfolio in FY27 and what the "Biosimilars" growth means for your healthcare holdings. Get the expert take here.
